|1.||Trotter, James F: 3 articles (02/2014 - 05/2003)|
|2.||Almenar, L: 3 articles (10/2010 - 11/2005)|
|3.||Kam, Igal: 3 articles (07/2010 - 05/2003)|
|4.||Neumann, Ulf P: 3 articles (08/2005 - 05/2002)|
|5.||Neuhaus, Peter: 3 articles (08/2005 - 05/2002)|
|6.||Emre, S: 2 articles (11/2011 - 03/2001)|
|7.||Jennings, Linda W: 2 articles (10/2011 - 03/2002)|
|8.||Levy, Marlon F: 2 articles (10/2011 - 03/2002)|
|9.||Canter, Charles E: 2 articles (03/2011 - 05/2004)|
|10.||Salvador, A: 2 articles (10/2010 - 10/2006)|
02/01/2005 - "Induction therapy with RATG (group V) was associated with significantly improved survival and freedom from acute rejection, BOS, and infection when compared to OKT3 induction therapy (group IV). "
02/01/2005 - "An earlier impression that RATG is superior to OKT3 induction therapy has borne true in terms of overall survival and incidence of BOS, acute rejection and infection rates. "
11/01/2009 - "However, injection of human liver-derived lymphocytes treated with IL-2/OKT3 completely prevented HCV infection. "
08/01/2001 - "The linearized rate (events/100 patient days) of all infections at 3 months was 1.55 +/- 0.28 for RATG group 1 and 2.19 +/- 0.27 for OKT3 group 1 (P = NS). "
04/01/1999 - "After exposure of patients to OKT3 an increased incidence of infections and malignancies has been reported. "
12/07/2006 - "This study identifies immunosuppression, through the use of ATG or OKT3, as a predictive factor of tumor recurrence, and confirms the prognostic value of tumor differentiation."
05/01/1999 - "A previous clinical Phase I trial examined OKT3 as an immunomodulator for the treatment of cancer. "
07/01/2015 - "In the current research, CD133 expression in primary CRC was detected by immunohistochemistry, and an asymmetric BiAb consisting of monomer of chimeric AC133 (mouse anti-human CD133 monoclonal antibody) and single chain of humanized OKT3 was developed to eradicate CD133-expressing tumor cells by arming activated T cells in vitro and in vivo. "
12/01/2002 - "The cytolytic efficiency of this antibody was comparable to that of a previously described bsAb, HEA125 x OKT3, targeting preactivated T lymphocytes against Ep-CAM-carrying tumor cells. "
03/01/2002 - "OKT3 use and rejection did not show significance in tumor development. "
|3.||Delayed Graft Function
09/01/1992 - "Indirect evidence exists that a prophylactic course of OKT3 may be beneficial in immunologically high-risk patients and in patients with delayed graft function. "
02/01/1990 - "Improved results using OKT3 as induction immunosuppression in renal allograft recipients with delayed graft function."
10/01/1991 - "Reduced delayed graft function (DGF) after cadaveric kidney transplantation (CKT) with selective OKT3 induction and aggressive intraoperative management."
02/01/1990 - "We conclude that OKT3 induction provides superior results over CsA induction at doses given in renal allograft recipients with delayed graft function without a significant increase in morbidity or mortality and permits the reuse of OKT3 for treatment of rejection in most cases."
11/01/1989 - "OKT3 prophylaxis in cadaveric kidney transplant recipients with delayed graft function."
02/01/2004 - "The use of OKT3 for treatment of advanced high-grade acute rejection episodes eventually can result in cytokine release and consecutive pulmonary edema. "
01/01/1994 - "Furthermore, the occurrence of pulmonary edema was directly related to OKT3 administration in 7 OKT3 patients (41%), whereas only 20 cases (24%) occurred in the extant OLT patients (p < 0.001). "
12/01/1995 - "Increased risk of pulmonary edema in diabetic patients undergoing preemptive pancreas transplantation with OKT3 induction."
04/01/1993 - "Cardiopulmonary effects of OKT3: determinants of hypotension, pulmonary edema, and cardiac dysfunction."
01/01/1996 - "OKT3 nephrotoxicity might have been favored by restriction of perioperative fluid infusion to prevent pulmonary edema and by the use of very high dose (30 mg/kg) of methylprednisolone (mPDS) before the first OKT3 injection to reduce the release of cytokines. "
|5.||Melanoma (Melanoma, Malignant)
01/01/1990 - "Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3."
08/01/1993 - "In the 16 patients with melanoma who received OKT3 plus IL-2, there was a single objective response (complete response). "
04/01/1983 - "Functional T-cell subpopulations have been evaluated in the peripheral blood of 124 melanoma patients (71 non-metastatic and 53 metastatic) using monoclonal antibodies: OKT3, OKT4, OKT8, every 2 months for 1 year. "
04/01/1995 - "A patient with renal cell cancer treated at the 600-micrograms/m2 OKT3 dose level experienced a 4-month partial remission, and two mixed responses were observed in a sarcoma and a melanoma patient treated at 100- and 400-micrograms/m2 OKT3 dose levels, respectively. "
08/01/1993 - "We performed a phase IB trial of a murine monoclonal anti-CD3 antibody (OKT3) with high-dose IL-2 in patients with advanced melanoma and renal cell carcinoma. "
|2.||Antilymphocyte Serum (Anti-Thymocyte Globulin)
|3.||HLA-A Antigens (HLA-A)
|5.||HLA-DR Antigens (HLA-DR)
|6.||DNA (Deoxyribonucleic Acid)
|7.||Immunoglobulin G (IgG)
|1.||Homologous Transplantation (Allograft)
|2.||Transplantation (Transplant Recipients)